Filing Details
- Accession Number:
- 0001209191-21-044040
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-30 18:02:57
- Reporting Period:
- 2021-06-28
- Accepted Time:
- 2021-06-30 18:02:57
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1826457 | Monte Rosa Therapeutics Inc. | GLUE | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559827 | Jr. A. Anthony Florence | 5425 Wisconsin Avenue Suite 800 Chevy Chase MD 20815 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-06-28 | 2,715,968 | $0.00 | 2,715,968 | No | 4 | C | Indirect | See Note 2 |
Common Stock | Acquisiton | 2021-06-28 | 3,257,328 | $0.00 | 5,973,296 | No | 4 | C | Indirect | See Note 2 |
Common Stock | Acquisiton | 2021-06-28 | 669,002 | $0.00 | 6,642,298 | No | 4 | C | Indirect | See Note 2 |
Common Stock | Acquisiton | 2021-06-28 | 1,050,000 | $19.00 | 7,692,298 | No | 4 | P | Indirect | See Note 2 |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Note 2 |
No | 4 | C | Indirect | See Note 2 |
No | 4 | C | Indirect | See Note 2 |
No | 4 | P | Indirect | See Note 2 |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A-2 convertible preferred stock | Disposition | 2021-06-28 | 9,588,725 | $0.00 | 2,715,968 | $0.00 |
Common Stock | Series B convertible preferred stock | Disposition | 2021-06-28 | 11,500,000 | $0.00 | 3,257,328 | $0.00 |
Common Stock | Series C convertible preferred Stock | Disposition | 2021-06-28 | 2,361,912 | $0.00 | 669,002 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
- The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.